{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:11:39Z","timestamp":1785435099931,"version":"3.56.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy: Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.omton.2024.200825","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T01:42:11Z","timestamp":1718242931000},"page":"200825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6857-4756","authenticated-orcid":false,"given":"Nawal","family":"Amhis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Carignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1176-4941","authenticated-orcid":false,"given":"Lee-Hwa","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2024.200825_bib1","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1200\/EDBK_280901","article-title":"Moving Beyond Chemotherapy for Pancreaticobiliary Tumors: Targeted and Immunotherapy Strategies","volume":"40","author":"Allen","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.omton.2024.200825_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated Projection of US Cancer Incidence and Death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.omton.2024.200825_bib3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic Cancer: A Review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.omton.2024.200825_bib4","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.omton.2024.200825_bib5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/gutjnl-2014-308653","article-title":"Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages","volume":"64","author":"Yu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.omton.2024.200825_bib6","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1097\/MPA.0000000000002301","article-title":"Cell of Origin of Pancreatic cancer: Novel Findings and Current Understanding","volume":"53","author":"Zheng","year":"2024","journal-title":"Pancreas"},{"key":"10.1016\/j.omton.2024.200825_bib7","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omton.2024.200825_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.omton.2024.200825_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.omton.2024.200825_bib10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","article-title":"Pancreatic Cancer","volume":"362","author":"Hidalgo","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib11","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omton.2024.200825_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12957-016-1078-z","article-title":"Preoperative predictors for early recurrence of resectable pancreatic cancer","volume":"15","author":"Nishio","year":"2017","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.omton.2024.200825_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2024.200825_bib15","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211045861","article-title":"Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma","volume":"13","author":"Iyengar","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib17","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1245\/s10434-023-14585-y","article-title":"ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer","volume":"31","author":"Turner","year":"2024","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib18","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1200\/JCO.2021.39.3_suppl.377","article-title":"Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas","volume":"39","author":"Katz","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib20","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2024.200825_bib21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib22","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib23","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.hoc.2024.01.004","article-title":"Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer","volume":"38","author":"Liu","year":"2024","journal-title":"Hematol.Oncol. Clin. North Am."},{"key":"10.1016\/j.omton.2024.200825_bib25","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement","volume":"274","author":"Jolissaint","year":"2021","journal-title":"Ann. Surg."},{"key":"10.1016\/j.omton.2024.200825_bib26","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann. Surg."},{"key":"10.1016\/j.omton.2024.200825_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91823-x","article-title":"Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study","volume":"11","author":"Yin","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2024.200825_bib28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \u201cvery early\u201d intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.omton.2024.200825_bib29","doi-asserted-by":"crossref","first-page":"3779","DOI":"10.1245\/s10434-013-3127-y","article-title":"Intra-arterial Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis","volume":"20","author":"Hyder","year":"2013","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib31","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.omton.2024.200825_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","article-title":"Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections","volume":"258","author":"Nagino","year":"2013","journal-title":"Ann. Surg."},{"key":"10.1016\/j.omton.2024.200825_bib33","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1432-2277.2010.01108.x","article-title":"Liver transplantation for cholangiocarcinoma","volume":"23","author":"Rosen","year":"2010","journal-title":"Transpl. Int."},{"key":"10.1016\/j.omton.2024.200825_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ags3.12734","article-title":"Essential updates 2021\/2022: Update in surgical strategy for perihilar cholangiocarcinoma","volume":"7","author":"Kawano","year":"2023","journal-title":"Ann. Gastroenterol. Surg."},{"key":"10.1016\/j.omton.2024.200825_bib35","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br. J. Surg."},{"key":"10.1016\/j.omton.2024.200825_bib37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study","volume":"37","author":"Edeline","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib40","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib41","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib42","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib43","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib44","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2021.39.15_suppl.4138","article-title":"Efficacy and safety of KN046 plus nab-paclitaxel\/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)","volume":"39","author":"Jin","year":"2021","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib45","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.2022.40.4_suppl.560","article-title":"Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial","volume":"40","author":"Fu","year":"2022","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib46","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib47","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.omton.2024.200825_bib48","article-title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM \u00c9vid."},{"key":"10.1016\/j.omton.2024.200825_bib49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/cco-21-174","article-title":"Immunotherapy in pancreatic cancer\u2014an emerging role: a narrative review","volume":"11","author":"Rangelova","year":"2022","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","article-title":"Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features","volume":"121","author":"Karamitopoulou","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2024.200825_bib51","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/gutjnl-2015-309193","article-title":"Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy","volume":"65","author":"Di Caro","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.omton.2024.200825_bib52","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.4103\/jcrt.jcrt_91_21","article-title":"Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer","volume":"18","author":"Zhang","year":"2022","journal-title":"J.\u00a0Cancer Res. Therapeut."},{"key":"10.1016\/j.omton.2024.200825_bib53","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T\u00a0cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200825_bib55","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omton.2024.200825_bib56","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omton.2024.200825_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nrgastro.2011.222","article-title":"The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma","volume":"9","author":"Sirica","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omton.2024.200825_bib59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3892\/ijo.2023.5585","article-title":"Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)","volume":"63","author":"Yang","year":"2023","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib60","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/s12935-020-01687-w","article-title":"Intrahepatic cholangiocarcinoma induced M2-polarized tumor-associated macrophages facilitate tumor growth and invasiveness","volume":"20","author":"Yuan","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omton.2024.200825_bib61","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1038\/bjc.2013.610","article-title":"Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer","volume":"109","author":"Goeppert","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2024.200825_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.727","article-title":"Forkhead box M1 recruits FoxP3+ Treg cells to induce immune escape in hilar cholangiocarcinoma","volume":"10","author":"Ma","year":"2022","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.omton.2024.200825_bib63","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib64","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.soc.2019.02.012","article-title":"Adoptive T-Cell Therapy for Solid Malignancies","volume":"28","author":"Jafferji","year":"2019","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"10.1016\/j.omton.2024.200825_bib65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","article-title":"Adoptive cell therapy for the treatment of patients with metastatic melanoma","volume":"21","author":"Rosenberg","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.omton.2024.200825_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CJI.0000000000000111","article-title":"Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer","volume":"39","author":"Meng","year":"2016","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors","volume":"4","author":"Hall","year":"2016","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200825_bib68","doi-asserted-by":"crossref","first-page":"TPS2650","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2650","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers","volume":"37","author":"Amaria","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib69","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00595-006-3201-1","article-title":"Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis Successfully Treated by Immunotherapy with CD3-Activated T Cells and Dendritic Cells After Surgery: Report of a Case","volume":"36","author":"Higuchi","year":"2006","journal-title":"Surg. Today"},{"key":"10.1016\/j.omton.2024.200825_bib70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.omton.2024.200825_bib71","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL Therapy: Facts and Hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib72","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200825_bib73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200825_bib74","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy","volume":"8","author":"Efremova","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200825_bib75","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T\u00a0cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200825_bib76","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.3390\/cancers12113344","article-title":"Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma","volume":"12","author":"Gokuldass","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2024.200825_bib77","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T\u00a0cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200825_bib78","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200825_bib79","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib80","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omton.2024.200825_bib81","first-page":"4606","article-title":"Facts and Hopes in Immunotherapy of Pancreatic Cancer","volume":"28","author":"Bockorny","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib82","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev-cancerbio-060820-111701","article-title":"Personal Neoantigen Vaccines for the Treatment of Cancer","volume":"5","author":"Shetty","year":"2021","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.omton.2024.200825_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696791","article-title":"Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines","volume":"12","author":"Stephens","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200825_bib84","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omton.2024.200825_bib85","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00262-005-0102-x","article-title":"Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin","volume":"55","author":"Wobser","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib86","first-page":"419","article-title":"Advances in immunotherapy for pancreatic ductal adenocarcinoma","volume":"28","author":"Miyazawa","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.omton.2024.200825_bib87","first-page":"3575","article-title":"MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer","volume":"25","author":"Yamamoto","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib88","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00262-008-0477-6","article-title":"Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers","volume":"57","author":"Toubaji","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib89","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000152","article-title":"New molecular and immunotherapeutic approaches in biliary cancer","volume":"2","author":"Goldstein","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.omton.2024.200825_bib90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/CJI.0b013e3181fb65b9","article-title":"Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer","volume":"34","author":"Kaida","year":"2011","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1479-5876-12-61","article-title":"Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer","volume":"12","author":"Aruga","year":"2014","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omton.2024.200825_bib92","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","article-title":"Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients","volume":"6","author":"Truxova","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.omton.2024.200825_bib93","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1038\/s41467-020-19781-y","article-title":"Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma","volume":"11","author":"Melaiu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200825_bib94","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","article-title":"Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape","volume":"38","author":"Garg","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.omton.2024.200825_bib95","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2024.200825_bib96","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3389\/fimmu.2019.00766","article-title":"Personalized Dendritic Cell Vaccines\u2014Recent Breakthroughs and Encouraging Clinical Results","volume":"10","author":"Mastelic-Gavillet","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200825_bib97","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2024.200825_bib98","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S1470-2045(13)70585-0","article-title":"Clinical use of dendritic cells for cancer therapy","volume":"15","author":"Anguille","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/CJI.0000000000000063","article-title":"A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A\u22170201 peptides for immunotherapy of metastatic hormone refractory prostate cancer","volume":"38","author":"Prue","year":"2015","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib100","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib101","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00262-002-0317-z","article-title":"Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I\/II clinical trial","volume":"51","author":"Pecher","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10238-011-0159-0","article-title":"A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer","volume":"12","author":"Rong","year":"2012","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.omton.2024.200825_bib103","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-14-0314","article-title":"Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms\u2019 Tumor 1 (WT1)\u2013Specific MHC Class I\/II\u2013Restricted Epitopes for Pancreatic Cancer","volume":"20","author":"Koido","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib104","first-page":"955","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2008","journal-title":"Cancer Ther."},{"key":"10.1016\/j.omton.2024.200825_bib105","first-page":"2217","article-title":"WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study","volume":"38","author":"Yanagisawa","year":"2018","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib106","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s11605-013-2286-2","article-title":"Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer","volume":"17","author":"Kobayashi","year":"2013","journal-title":"J.\u00a0Gastrointest. Surg."},{"key":"10.1016\/j.omton.2024.200825_bib107","first-page":"171","article-title":"Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma","volume":"19","author":"Shimizu","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.omton.2024.200825_bib108","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00262-024-03632-6","article-title":"Clinical immunotherapy in pancreatic cancer","volume":"73","author":"Ye","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2024.200825_bib109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","article-title":"Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor\u2013Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation","volume":"19","author":"Jaffee","year":"2001","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","article-title":"Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes\u2013Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer","volume":"33","author":"Le","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omton.2024.200825_bib111","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-20-2974","article-title":"Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma","volume":"27","author":"Zheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib112","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2024.200825_bib113","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A Phase II Study of Allogeneic GM-CSF\u2013Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2024.200825_bib114","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3892\/ol.2021.12670","article-title":"Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells","volume":"21","author":"Chen","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omton.2024.200825_bib115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200825_bib116","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T\u00a0cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.omton.2024.200825_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216636","article-title":"Precision treatment of pancreatic ductal adenocarcinoma","volume":"585","author":"Wei","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omton.2024.200825_bib118","article-title":"Organoid Models for Precision Cancer Immunotherapy","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2024.200825_bib119","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.omton.2024.200825_bib120","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","article-title":"Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class","volume":"8","author":"Samuel","year":"2022","journal-title":"JAMA Oncol."}],"container-title":["Molecular Therapy: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329924000675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T18:43:51Z","timestamp":1732214631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924000675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":120,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950329924000675"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2024.200825","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transforming pancreaticobiliary cancer treatment: Exploring the frontiers of adoptive cell therapy and cancer vaccines","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy: Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2024.200825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"200825"}}